{
    "nct_id": "NCT04185883",
    "official_title": "A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)",
    "inclusion_criteria": "* Men or women greater than or equal to 18 years old.\n* Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements. In the United States, this test must be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Primary brain tumor.\n* Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or leptomeningeal disease from non-brain tumors.\n* Myocardial infarction within 6 months of study day 1.\n* Gastrointestinal (GI) tract disease causing the inability to take oral medication.",
    "miscellaneous_criteria": ""
}